This is an aggregated industry headline. Read the full story at FierceBiotech →
Sanofi's R&D chief Ashrafian to hit the exit as new CEO seeks to fix stuttering pipeline with Roche alum
Recently appointed Sanofi CEO Belén Garijo has stamped her mark on the organization, hiring Paulo Fontoura, M.D., Ph.D., to replace Houman Ashrafian, Ph.D., as the head of the company's stuttering R&D group.
By FierceBiotech
· Jun 22, 2026
· via FierceBiotech
Image: FierceBiotech
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineFierceBiotech
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
Despite a major curveball thrown by the FDA earlier this year, Moderna has managed to strike true with a U.S. …
The WeekFierceBiotech ↗
A little over a year ago, LifeMine Therapeutics laid off staff and put its fungus-based platform on ice to foc…
The WeekBriefing
Takeda won FDA approval for Orzeyful in adults with narcolepsy type 1. The decision introduces the first appro…